𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase II trial of oral 4′ demethoxydaunorubicin (DMDR) in inoperable non small cell lung cancer

✍ Scribed by P. Presgrave; R. Woods; R. Kefford; D. Bell; D. Raghavan; J. Levi

Publisher
Springer US
Year
1988
Tongue
English
Weight
216 KB
Volume
6
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

✦ Synopsis

4' Demethoxydaunorubicin, an orally active daunorubicin analogue, was administered to 22 patients with inoperable non small cell lung cancer (NSCLC). Patients were stratified into good and poor risk categories and received doses of 45 mg/m 2 and 40 mg/m 2 respectively at 28 day intervals. All 22 patients were evaluable for response: No tumour responses occurred. Therapy was well tolerated. Mild gastrointestinal toxicity occurred in 41% of patients. Leucopenia with a wcc < 3 x 109/L occurred in 33% of patients and thrombocytopenia < 100 x 109/L in 9%. Severe marrow toxicity was rare and there appeared to be no difference in terms of toxicity between the different dose levels. DMDR appears to have no useful clinical activity in NSCLC.

📜 SIMILAR VOLUMES

Oral 4-demethoxydaunorubicin (idarubicin
Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; Phase II trial
✍ Howard S. Hochster; Michael D. Green; Ronald H. Blum; James C. Wernz; James L. S 📂 Article 📅 1986 🏛 Springer US 🌐 English ⚖ 258 KB

Eighteen patients with non-small cell lung cancer were entered into a phase II protocol of oral 4-demethoxydaunorubicin. All were evaluable for toxicity and 17 for response. The major toxicity was hematologic with eight patients developing an ECOG grade 3 or 4 toxicity. There were no responses to th

Phase II clinical and pharmacological st
Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer
✍ Robert Milroy; Jeffrey Cummings; Stanley B. Kaye; Stephen W. Banham 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 298 KB

4-Demethoxydaunorubicin (4-DMDNR) is an oral anthracycline with antitumour activity demonstrated in a number of clinical studies. We have assessed the usefulness of 4-DMDNR in 16 patients with advanced small cell lung cancer, none of whom had received previous chemotherapy. There were no complete or

A phase II trial of oral tegafur and ura
A phase II trial of oral tegafur and uracil plus cisplatin in patients with inoperable nonsmall cell lung cancer
✍ Yukito Ichinose; Nobuko Takanashi; Tokujiro Yano; Hiroshi Asoh; Hideki Yokoyama; 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 391 KB 👁 2 views

## Background: The combination of uracil and tegafur in a 4:1 molar concentration (uft) has a greater antitumor activity than 5-fluorouracil (5-fu) and tegafur. because the combination of 5-fu and cisplatin has been proven to have a synergistic antitumor effect in many experimental and clinical stu